A countdown to failure for Valeant's hostile $53B Allergan takeover

Activist investor Bill Ackman urges shareholders to take action before time runs out on Valeant Pharmaceuticals' hostile $53 billion bid to acquire Allergan.

Pershing Capital Management, Valeant Pharmaceuticals, Allergan Inc.

News Well, Cosmetic/Aesthetic, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1moLdXv